EMA Modernizes Orphan Drug Process
The agency launched a secure online portal for orphan drug designation applications.
On June 19, 2018, the European Medicines Agency (EMA) announced the launch of “Iris”, a secure online portal for the submission of orphan drug designation applications. The new portal will allow applicants to submit and manage information and documents related to their application. The agency hopes the portal will reduce the time needed to prepare and submit applications.
Part of a long-term program to handle product-related applications and utilize master data in pharmaceutical regulatory processes, Iris allows applicants to check the status of their applications and receive automatic notifications of changes.
While the existing submission process will be available until Sept. 19, 2018, EMA is encouraging companies to start using the new portal. The agency has developed two new guidance documents with step-by-step instructions on how to use the new system.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
